Abstract
In the past decades, there was an improvement in survival in pediatric heart transplantation. Despite advances in immunosuppression therapy and the pharmacogenetics of these patients, the lymphoproliferative disease still remains a limiting factor in survival. There are few studies evaluating lymphoproliferative disease and the risk factors associated with this condition which has motivat…